Antibe closes public offering

On August 13, 2019, Antibe Therapeutics Inc. ("Antibe") announced that closed its previously announced public offering of 26,833,332 units at a price of C$0.30 per unit for aggregate gross proceeds of C$8,050,000.

The units were offered and sold by way of a short form prospectus filed in Alberta, British Columbia, Manitoba, Ontario and Saskatchewan, pursuant to an amended and restated agency agreement effective August 7, 2019 with a syndicate of agents led by Bloom Burton Securities Inc., together with Echelon Wealth Partners Inc., Dominick Capital Corporation and Industrial Alliance Securities Inc. Each unit was comprised of one common share of Antibe and one-half of one common share purchase warrant. Each full warrant is exercisable to purchase one common share at any time prior to August 13, 2022 at a price of C$0.40 per common share.

Antibe intends to use the net proceeds of the offering to fund certain activities in preparation for planned meetings with regulatory agencies and eventual global partnering discussions anticipated to commence subsequent to the completion of the on-going Phase 2B dose-ranging, efficacy study for ATB-346, a non-addictive analgesic for treating severe acute pain.

Further information can be found on Business Wire's website.

Antibe is a leader in developing safer therapeutics for pain and inflammation.